HLS Therapeutics Inc.
HLTRF
$2.72
$0.082.96%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 55.59% | -72.06% | 65.93% | -42.94% | 38.21% |
| Total Depreciation and Amortization | -0.18% | 1.34% | -0.87% | 0.51% | 2.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -35.99% | -541.73% | -91.43% | 180.62% | -13.73% |
| Change in Net Operating Assets | -120.60% | 67.05% | 403.11% | -157.55% | -34.12% |
| Cash from Operations | -54.45% | -2.15% | 162.80% | -46.22% | 29.95% |
| Capital Expenditure | -- | -- | 48.44% | 26.44% | -314.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 84.33% | -35.34% | -31.63% | 78.50% | -- |
| Cash from Investing | 84.33% | -21.20% | -13.26% | 74.33% | -5,076.19% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | 76.91% | -1.31% | 91.15% | -579.76% | -178.18% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | 99.11% | 6.00% | -373.30% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 86.23% | -- | -- |
| Cash from Financing | 76.68% | 1.99% | -55.87% | 63.61% | -188.66% |
| Foreign Exchange rate Adjustments | -74.17% | -198.36% | 195.31% | -134.88% | 948.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 132.84% | -36.19% | 168.73% | 75.36% | -2,107.55% |